(Q38964271)

8 September 2017

title

Zoledronic acid induces apoptosis and autophagy in cervical cancer cells (English)

1 reference

8 September 2017

0 references

1 reference

cervix uterine cancer

1 reference

I-Te Wang

1

1 reference

8 September 2017

Shou-Chu Chou

series ordinal

2

1 reference

8 September 2017

Ying-Chin Lin

series ordinal

3

1 reference

8 September 2017

publication date

21 August 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

35

1 reference

8 September 2017

issue

12

1 reference

8 September 2017

page(s)

11913-11920

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-014-2460-5

8 September 2017

exact match

0 references

cites work

The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Distant metastases from cervical esophagus cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Prognostic factors in advanced stage squamous cell cancer of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Bone metastasis in cervical cancer patients over a 10-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Antitumor effects and anticancer applications of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid: an unending tale for an antiresorptive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid inhibits human osteoblast activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Endometrial cancer diagnosed by the presence of bone metastasis and treated with zoledronic Acid: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Cytokines and insulin resistance after zoledronic acid-induced acute phase response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid - a multiplicity of anti-cancer action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Bisphosphonates: preclinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Significance and impact of bisphosphonate-induced acute phase responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2460-5

Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

21 January 2018

1 reference

12 December 2020

Immunohistochemical expression of caspase-3, caspase-5, caspase-7 and apoptotic protease-activating factor-1 (APAF-1) in the liver and kidney of rats exposed to zoledronic acid (ZOL) and basic fibroblast growth factor (bFGF)

1 reference

12 December 2020

Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents

1 reference

12 December 2020

Biology of osteoclast activation in cancer

1 reference

12 December 2020

Zoledronic acid induces autophagic cell death in human prostate cancer cells

1 reference

12 December 2020

The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients

1 reference

12 December 2020

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

1 reference

12 December 2020

Antineoplastic activity of zoledronic acid and denosumab

1 reference

12 December 2020

A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer

1 reference

12 December 2020

Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma

1 reference

12 December 2020

10.1007/S13277-014-2460-5

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1036820969

0 references

1 reference